SaaSBiotech & Life SciencesHealthcareConsumerFintechAIClimate & EnergyRobotics & AutomationEnterprise SoftwareData & Analytics
Boston Harbor Angels is a group of proven business leaders who invest personal capital in high-growth, early-stage companies, typically raising $250K to $1.5M. Founded in 2004, the group invests across a broad range of sectors including information technology, life sciences, consumer products, medical devices, and clean technology, providing both funding and mentorship to entrepreneurs.
67% of their portfolio is in Biotech & Life Sciences. They made 1 investments in the last 12 months. Their most common stage is series-a (50% of deals). Average disclosed round size is $5.5M (across 5 rounds with reported amounts).
Portfolio
4
Fund Size
—
Top Stage
Series A
Last 12 Mo
1
Team
Portfolio Breakdown
Stage Distribution
Investment Activity
DealsAvg Round Size
Portfolio
6 investments
| Company | Round | Amount | Date |
|---|---|---|---|
| GGelmedix | Seed | $13M | Feb 2026 |
 Zylo Therapeutics | Series B | $5.2M | Jun 2022 |
 Avaxia | Series A | $4.1M | Feb 2012 |
| Avaxia | Series A | $2.2M | Nov 2011 |
| Zylo Therapeutics | Series A | — | — |
 S'More Date | Seed | $3.2M | — |
Top Co-Investors
New York Angels2 shared
Keiretsu Forum2 shared
HTL Biotechnology1 shared
Safar Partners1 shared
TiE Boston Angels1 shared
Benson Oak Ventures1 shared
Gaingels1 shared
Launchpad Capital1 shared
Last updated: 8 September 2026